不可切除的中晚期肝细胞癌患者的转化治疗：现实世界队列的比较分析

IF 2.7 3区医学 Q1 SURGERY

American journal of surgery Pub Date : 2025-09-01 DOI:10.1016/j.amjsurg.2025.116602

Yangyang Ou , Yiyu Chen , Kang Chen , Ming Yao, Guanglin Ling, Chun Liao, Yanlong Liu, Haizhao Cao, Jianjun Li, Chunming Wang, Yuanneng Nong, Ji'an Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan

{"title":"不可切除的中晚期肝细胞癌患者的转化治疗：现实世界队列的比较分析","authors":"Yangyang Ou , Yiyu Chen , Kang Chen , Ming Yao, Guanglin Ling, Chun Liao, Yanlong Liu, Haizhao Cao, Jianjun Li, Chunming Wang, Yuanneng Nong, Ji'an Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan","doi":"10.1016/j.amjsurg.2025.116602","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Conversion therapy offers new hope for patients with unresectable hepatocellular carcinoma (uHCC), thereby becoming a pivotal advancement in the field of liver cancer treatment.</div></div><div><h3>Methods</h3><div>This study consecutively collected clinical data of patients who received different conversion therapy regimens from June 2020 to March 2024, and retrospectively analyzed their efficacy and survival prognosis.</div></div><div><h3>Results</h3><div>In this study, the conversion success rate of patients with uHCC after conversion therapy was 20.4 %. Patients who successfully converted had a better long-term prognosis than those who failed. Compared with patients treated with combination therapy, the conversion rate and objective response rate of single local treatment were lower.</div></div><div><h3>Conclusions</h3><div>The choice of conversion therapy is crucial for the prognosis of patients with uHCC. The triple therapy of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with Tyrosine Kinase Inhibitor (TKI) and Immune Checkpoint Inhibitor (ICI) demonstrates favorable outcomes and manageable safety profiles.</div></div>","PeriodicalId":7771,"journal":{"name":"American journal of surgery","volume":"250 ","pages":"Article 116602"},"PeriodicalIF":2.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative analysis in a real-world cohort\",\"authors\":\"Yangyang Ou , Yiyu Chen , Kang Chen , Ming Yao, Guanglin Ling, Chun Liao, Yanlong Liu, Haizhao Cao, Jianjun Li, Chunming Wang, Yuanneng Nong, Ji'an Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan\",\"doi\":\"10.1016/j.amjsurg.2025.116602\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Conversion therapy offers new hope for patients with unresectable hepatocellular carcinoma (uHCC), thereby becoming a pivotal advancement in the field of liver cancer treatment.</div></div><div><h3>Methods</h3><div>This study consecutively collected clinical data of patients who received different conversion therapy regimens from June 2020 to March 2024, and retrospectively analyzed their efficacy and survival prognosis.</div></div><div><h3>Results</h3><div>In this study, the conversion success rate of patients with uHCC after conversion therapy was 20.4 %. Patients who successfully converted had a better long-term prognosis than those who failed. Compared with patients treated with combination therapy, the conversion rate and objective response rate of single local treatment were lower.</div></div><div><h3>Conclusions</h3><div>The choice of conversion therapy is crucial for the prognosis of patients with uHCC. The triple therapy of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with Tyrosine Kinase Inhibitor (TKI) and Immune Checkpoint Inhibitor (ICI) demonstrates favorable outcomes and manageable safety profiles.</div></div>\",\"PeriodicalId\":7771,\"journal\":{\"name\":\"American journal of surgery\",\"volume\":\"250 \",\"pages\":\"Article 116602\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002961025004258\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002961025004258","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

摘要

背景转化疗法为不可切除的肝细胞癌患者带来了新的希望，成为肝癌治疗领域的关键进展。方法本研究连续收集2020年6月至2024年3月接受不同转换治疗方案患者的临床资料，回顾性分析其疗效及生存预后。结果本组原发性肝癌患者经转化治疗后，转化成功率为20.4%。成功转换的患者比失败的患者有更好的长期预后。与联合治疗的患者相比，单纯局部治疗的转换率和客观有效率较低。结论转换治疗的选择对原发性肝癌患者的预后至关重要。肝动脉输注化疗（HAIC）联合酪氨酸激酶抑制剂（TKI）和免疫检查点抑制剂（ICI）的三联疗法显示出良好的结果和可控的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative analysis in a real-world cohort

Background

Conversion therapy offers new hope for patients with unresectable hepatocellular carcinoma (uHCC), thereby becoming a pivotal advancement in the field of liver cancer treatment.

Methods

This study consecutively collected clinical data of patients who received different conversion therapy regimens from June 2020 to March 2024, and retrospectively analyzed their efficacy and survival prognosis.

Results

In this study, the conversion success rate of patients with uHCC after conversion therapy was 20.4 %. Patients who successfully converted had a better long-term prognosis than those who failed. Compared with patients treated with combination therapy, the conversion rate and objective response rate of single local treatment were lower.

Conclusions

The choice of conversion therapy is crucial for the prognosis of patients with uHCC. The triple therapy of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with Tyrosine Kinase Inhibitor (TKI) and Immune Checkpoint Inhibitor (ICI) demonstrates favorable outcomes and manageable safety profiles.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American journal of surgery 医学-外科

CiteScore

5.00

自引率

6.70%

发文量

570

审稿时长

56 days

期刊介绍： The American Journal of Surgery® is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery. AJS is the official journal of 7 major surgical societies* and publishes their official papers as well as independently submitted clinical studies, editorials, reviews, brief reports, correspondence and book reviews.